Nipocalimab for Systemic Lupus Erythematosus

(GARDENIA-SLE Trial)

This trial aims to evaluate how well a new treatment, nipocalimab, works for individuals with moderate to severe systemic lupus erythematosus (SLE). SLE occurs when the immune system attacks the body's own tissues, causing swelling and redness in various organs. Participants will receive either nipocalimab or a placebo, alongside their regular care, for up to 52 weeks. Individuals who have had SLE for at least six months and experience active symptoms that disrupt daily life may be suitable for this trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to potentially bringing a new treatment to market.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that nipocalimab is generally safe for people with systemic lupus erythematosus (SLE). Studies have found no new safety issues compared to past trials. Participants in earlier studies did not experience unexpected side effects. The safety profile of nipocalimab is similar to other treatments, suggesting it is manageable for patients. While no treatment is without risk, current evidence supports the safety of nipocalimab for those considering joining a clinical trial.¹²³⁴⁵

Nipocalimab is unique because it targets the neonatal Fc receptor (FcRn), a new approach for treating Systemic Lupus Erythematosus (SLE). Unlike standard treatments like corticosteroids and immunosuppressants, which broadly suppress the immune system, nipocalimab specifically reduces the levels of pathogenic antibodies without broadly impacting immune function. Researchers are excited about nipocalimab because this targeted action could lead to fewer side effects and a more effective way to manage SLE, potentially improving patient quality of life.

Research has shown that nipocalimab, which participants in this trial may receive, may help treat systemic lupus erythematosus (SLE). In earlier studies, more patients who received nipocalimab showed improvement in lupus symptoms by week 24 compared to those who did not receive it. The JASMINE study found that nipocalimab met its main goal by reducing disease activity in SLE patients. This treatment blocks a protein called FcRn, which likely lowers harmful antibodies that attack the body's tissues in lupus. Overall, these findings suggest that nipocalimab may effectively reduce lupus symptoms.¹²⁴⁶⁷